Aptevo Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seattle WA United States (2016)

Organization Overview

First Clinical Trial
2016
NCT00614042
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2025

Timeline

NOW
  • Now

Alternative names

Aptevo BioTherapeutics | Aptevo Therapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 1)

Colitis, Ulcerative (Phase 1)

Hemophilia A (Phase 3)

Hemophilia B (Phase 3)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Prostatic Neoplasms (Phase 1)

Psoriasis (Phase 1)

Ulcer (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 10